宣泰医药
(688247)
| 流通市值：41.66亿 | | | 总市值：41.66亿 |
| 流通股本：4.53亿 | | | 总股本：4.53亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 94,546,671.06 | 446,568,888.08 | 331,464,771.67 | 219,607,034.66 |
| 营业收入 | 94,546,671.06 | 446,568,888.08 | 331,464,771.67 | 219,607,034.66 |
| 二、营业总成本 | 82,432,049.12 | 394,329,144.83 | 276,521,555.79 | 177,953,022.18 |
| 营业成本 | 57,696,405.85 | 270,542,117.19 | 196,182,373.59 | 129,059,238.3 |
| 税金及附加 | 936,899.05 | 3,383,378.44 | 2,589,019.59 | 1,585,056.54 |
| 销售费用 | 2,247,487.02 | 9,868,874.61 | 7,746,597.15 | 4,419,393.02 |
| 管理费用 | 8,343,884.6 | 37,131,600.71 | 28,823,979.19 | 18,642,446.79 |
| 研发费用 | 11,973,009.88 | 74,939,615.69 | 42,889,476.72 | 25,703,973.68 |
| 财务费用 | 1,234,362.72 | -1,536,441.81 | -1,709,890.45 | -1,457,086.15 |
| 其中:利息费用 | 81.74 | 1,411.72 | 1,132.17 | 652.84 |
| 其中:利息收入 | 1,475,052.1 | 5,320,657.35 | 3,381,610.27 | 1,831,761.53 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | - | 1,341,275.35 | - | - |
| 加:投资收益 | 617,185.25 | 9,911,414.57 | 9,181,763.05 | 6,829,858.09 |
| 资产减值损失(新) | -238,144.97 | -17,539,733.26 | -865,370.19 | -1,014,367.59 |
| 信用减值损失(新) | 1,468,545.63 | -1,453,006.6 | 1,521,203.91 | 1,697,598.45 |
| 其他收益 | 962,574.71 | 10,819,130.92 | 4,787,542.56 | 2,066,744.53 |
| 四、营业利润 | 14,924,782.56 | 55,318,824.23 | 69,568,355.21 | 51,233,845.96 |
| 加:营业外收入 | 3,468,974.8 | 37,308.85 | 8,763.49 | 5,486.5 |
| 减:营业外支出 | 18,460.71 | 2,020,799.66 | 279,441.15 | 213,502.11 |
| 五、利润总额 | 18,375,296.65 | 53,335,333.42 | 69,297,677.55 | 51,025,830.35 |
| 减:所得税费用 | 1,811,958.4 | 5,852,518.73 | 5,835,210.76 | 5,440,164.89 |
| 六、净利润 | 16,563,338.25 | 47,482,814.69 | 63,462,466.79 | 45,585,665.46 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 16,563,338.25 | 47,482,814.69 | 63,462,466.79 | 45,585,665.46 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 16,563,338.25 | 47,482,814.69 | 63,462,466.79 | 45,585,665.46 |
| 扣除非经常损益后的净利润 | 12,491,038.42 | 31,333,993.96 | 53,880,715.31 | 39,523,041.49 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.04 | 0.11 | 0.14 | 0.1 |
| (二)稀释每股收益 | 0.04 | 0.11 | 0.14 | 0.1 |
| 八、其他综合收益 | -16,043.8 | -20,861.17 | -12,932.76 | 357.33 |
| 归属于母公司股东的其他综合收益 | -16,043.8 | -20,861.17 | -12,932.76 | 357.33 |
| 九、综合收益总额 | 16,547,294.45 | 47,461,953.52 | 63,449,534.03 | 45,586,022.79 |
| 归属于母公司股东的综合收益总额 | 16,547,294.45 | 47,461,953.52 | 63,449,534.03 | 45,586,022.79 |
| 公告日期 | 2026-04-30 | 2026-04-30 | 2025-10-31 | 2025-08-23 |
| 审计意见(境内) | | 标准无保留意见 | | |